News & Commentary

Key Takeaways from Senate Group of Six Draft 340B Bill (Part 1)

(Part One of a Two-Part Analysis) After reviewing comments from over 250 stakeholders, meeting with various interest groups and holding regular staff meetings, the U.S. Senate bipartisan “Group of Six” have released a highly … [Read more...]

Action on 340B Contract Pharmacies Turns to the States

As we approach the 16-month mark since we had pivotal arguments over the 340B contract pharmacy program in two federal appellate courts and Congress continues to offer no relief, a growing number of 340B providers are turning to state legislatures … [Read more...]

Hospitals Are Not the Only 340B Providers Under Scrutiny

Long-time 340B observers were surprised to see that Sen. Bill Cassidy (R-La.) has expanded his 340B investigation into community health centers. In September, Cassidy, a long-time critic of the program, launched an inquiry into hospital use of the … [Read more...]

Why the Genesis 340B Patient Definition Court Decision Could Resolve the Contract Pharmacy Impasse

In what legal experts describe as a landmark decision, the U.S. District Court for the District of South Carolina ruled Nov. 3 that the plain wording of the 340B statute does not require a covered entity to have initiated a healthcare service … [Read more...]

Whether it is 340B Policy or Keeping the Lights On, House Chaos Underscores Senate’s Importance

According to our history lessons, George Washington told Thomas Jefferson that the Senate was created to serve as a saucer to “cool” the House’s hot cup of tea. … [Read more...]

Could the States Resolve the Contract Pharmacy Impasse?

After a recent lull in the ongoing battle over whether drug manufacturers can continue to place restrictions on access to 340B discounts in the contract pharmacy setting, things are heating up at the state level. … [Read more...]

The Big Question on the Minds of Every 340B Stakeholder

As we pass the third anniversary of the pharmaceutical industry’s surprise decision to significantly scale back access to 340B pricing in the contract pharmacy setting, the key question is:  Why is it taking so long to come up with a … [Read more...]

The Growing Inevitability of New 340B Reporting Requirements

Just before the end of most state legislative sessions for 2023, two states enacted the first ever 340B-specific reporting requirements for covered entities. As my colleague Will Newton reported in 340B Report, Minnesota was the first to enact a … [Read more...]

Lessons from Two State Legislatures and What They Mean for 340B Stakeholders

As many 2023 state legislative sessions come to an end, it is a good time to take a closer look at two states—one in the South and one in the Northeast—to see how they are tackling some of the most pressing matters impacting 340B stakeholders. … [Read more...]

Could We Have a Breakthrough in the Contract Pharmacy Battle?

As we reach the third-year mark since pharmaceutical manufacturers began to restrict access to 340B pricing in the contract pharmacy setting, we recently experienced a watershed moment that I believe will lead to an end of the standoff between the … [Read more...]